HIMS CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Hims & Hers Health, Inc.
LOS ANGELES--(BUSINESS WIRE)-- The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the Northern District of California, captioned Sookdeo v. Hims & Hers Health, Inc., et al., Case No. 3:25-cv-05315, on behalf of persons and entities that purchased or otherwise acquired Hims & Hers Health, Inc. ('Hims' or the 'Company') (NYSE: HIMS) securities between , inclusive (the 'Class Period'). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the 'Exchange Act').
HIMS CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Hims & Hers Health, Inc.
Share
Investors are hereby notified that they have until 60 days from this notice to move the Court to serve as lead plaintiff in this action.
IF YOU SUFFERED A LOSS ON YOUR HIMS INVESTMENTS, CLICK HERE TO SUBMIT A CLAIM TO POTENTIALLY RECOVER YOUR LOSSES IN THE ONGOING SECURITIES FRAUD LAWSUIT.
What Happened?
On April 29, 2025, Hims announced a long-term collaboration with Novo Nordisk, starting with the immediate sale of 'a bundled offering of Novo Nordisk's FDA-approved Wegovy on the Hims & Hers platform.'
On June 23, 2025, before the market opened, Novo Nordisk issued a press release announcing that it was terminating its partnership with Hims, 'based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.' The press release stated that Hims 'has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization.'' The press release further stated '[b]ased on Novo Nordisk's investigation, the 'semaglutide' active pharmaceutical ingredients that are in the knock-off drugs sold by telehealth entities and compounding pharmacies are manufactured by foreign suppliers in China' which 'FDA has never authorized or approved' and which may contain 'unsafe and illicit foreign ingredients.'
On this news, the Company's share price fell $22.24, or 34.6%, to close at $41.98 per share on June 23, 2025, on unusually heavy trading volume.
What Is The Lawsuit About?
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Hims was engaged in the 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk;' (2) that, as a result, there was a substantial risk that the Company's collaboration with Novo Nordisk would be terminated; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Contact Us To Participate or Learn More:
If you purchased Hims securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please HERE or contact us at:
Law Offices of Frank R. Cruz
2121 Avenue of the Stars, Suite 800
Telephone: 310-914-5007
Email: info@frankcruzlaw.com
Visit our website at: www.frankcruzlaw.com
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
39 minutes ago
- Business Upturn
Mars' Pending Acquisition of Kellanova Clears FTC Antitrust Review
CHICAGO, McLean, Va., United States: Mars, Incorporated, a family-owned, global leader in pet care, snacking and food, and Kellanova (NYSE: K), a leader in global snacking, international cereal and noodles and North America frozen foods, today announced that the U.S. Federal Trade Commission (FTC) has concluded its antitrust review of Mars' pending acquisition of Kellanova. Poul Weihrauch,CEO & Office of the President, Mars, Incorporated, said: 'We are very pleased that the FTC has completed its review of the transaction without the imposition of any condition or requiring any remedy. The transaction has now received all but one of the 28 required regulatory clearances, with only the review by the European Commission outstanding. This brings us one step closer to uniting two iconic businesses with complementary footprints and portfolios, allowing us to deliver more choice and innovation to consumers.' Steve Cahillane, Chairman, President & CEO, Kellanova, said: 'This represents a significant milestone on our path to combine Mars Snacking and Kellanova. We continue to believe this is an exciting opportunity to create a broader, global snacking business that is better positioned to meet evolving consumer needs and preferences.' Based on the current status of the ongoing antitrust review by the European Commission, Mars and Kellanova expect the transaction to close towards the end of 2025, subject to customary closing conditions. The exact timing cannot be predicted with any certainty at this point. About Mars, Incorporated Mars, Incorporated is driven by the belief that the world we want tomorrow starts with how we do business today. As a global, family-owned business, Mars is transforming, innovating, and evolving to make a positive impact on the world. Across our diverse and expanding portfolio of quality snacking, food, and pet care products and services, we employ 150,000+ dedicated Associates. With more than $50 billion in annual sales, we produce some of the world's best-loved brands including Ben's Original™, CESAR®, Cocoavia®, DOVE®, EXTRA®, KIND®, M&M's®, SNICKERS®, PEDIGREE®, ROYAL CANIN®, and WHISKAS®. We are creating A Better World for Pets through our global network of pet hospitals and diagnostic services – including AniCura, BANFIELD™, BLUEPEARL™, Linnaeus and VCA™ – using cutting edge technology to develop breakthrough programs in genetic health screening and DNA testing. For more information about Mars, please visit Join us on Facebook, Instagram, LinkedIn and YouTube. About Kellanova Kellanova (NYSE: K) is a leader in global snacking, international cereal and noodles, and North America frozen foods with a legacy stretching back more than 100 years. Powered by differentiated brands including Pringles®, Cheez-It®, Pop-Tarts®, Kellogg's Rice Krispies Treats®, RXBAR®, Eggo®, MorningStar Farms®, Special K®, Coco Pops®, and more, Kellanova's vision is to become the world's best-performing snacks-led company, unleashing the full potential of our differentiated brands and our passionate people. Our Net Sales for 2023 were $13 Billion. At Kellanova, our purpose is to create better days and ensure everyone has a seat at the table through our trusted food brands. We are committed to promoting sustainable and equitable food access by tackling the crossroads of hunger, sustainability, wellbeing, and equity, diversity & inclusion. Our goal is to create Better Days for 4 billion people by the end of 2030 (from a 2015 baseline). For more detailed information about our commitments, our approach to achieving these goals, and methodology, please visit our website at Forward-Looking Statements This press release, and any related oral statements, includes statements that constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended, including statements regarding the pending acquisition (the 'Merger') of Kellanova (the 'Company') by Mars, Incorporated ('Mars'), regulatory approvals, the expected timetable for completing the Merger, the expected benefits and other effects of the Merger, the integration of the companies, the combined business going forward and any other statements regarding the Company's future expectations, beliefs, plans, objectives, financial conditions, assumptions or future events or performance that are not historical facts. This information may involve risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. These risks and uncertainties include, but are not limited to: the timing to consummate the Merger and the risk that the Merger may not be completed at all or the occurrence of any event, change, or other circumstances that could give rise to the termination of the merger agreement, including circumstances requiring a party to pay the other party a termination fee pursuant to the merger agreement; the risk that the conditions to closing of the Merger may not be satisfied or waived; the risk that a governmental or regulatory approval that may be required for the Merger is not obtained or is obtained subject to conditions that are not anticipated; potential litigation relating to, or other unexpected costs resulting from, the Merger; legislative, regulatory, and economic developments; risks that the Merger disrupts the Company's current plans and operations; the risk that certain restrictions during the pendency of the Merger may impact the Company's ability to pursue certain business opportunities or strategic transactions; the diversion of management's time on transaction-related issues; continued availability of capital and financing and rating agency actions; the risk that any announcements relating to the Merger could have adverse effects on the market price of the Company's common stock, credit ratings or operating results; and the risk that the proposed transaction and its announcement could have an adverse effect on the ability to retain and hire key personnel, to retain customers and to maintain relationships with business partners, suppliers and customers. All statements, other than statements of historical fact, should be considered forward-looking statements made in good faith by the Company, as applicable, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. When used in this communication, or any other documents, words such as 'anticipate,' 'believe,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'objective,' 'plan,' 'project,' 'seek,' 'strategy,' 'target,' 'will' and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on the beliefs and assumptions of management at the time that these statements were prepared and are inherently uncertain. Such forward-looking statements are subject to risks and uncertainties that could cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements. These risks and uncertainties, as well as other risks and uncertainties that could cause the actual results to differ materially from those expressed in the forward-looking statements, are described in greater detail in the Company's reports filed with the United States Securities and Exchange Commission (the 'SEC'), including the Company's Annual Report on Form 10-K for the year ended December 28, 2024, subsequent Quarterly Reports on Form 10-Q, Current Reports on Forms 8-K and other SEC filings made by the Company. The Company cautions that these risks and factors are not exclusive. Management cautions against putting undue reliance on forward-looking statements or projecting any future results based on such statements or present or prior earnings levels. Forward-looking statements speak only as of the date of this Report, and, except as required by applicable law, the Company does not undertake any obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made. View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
an hour ago
- Yahoo
Perfect Corp. (PERF) Partners with NVIDIA to Enhance AI Beauty and Fashion Solutions
Perfect Corp. (NYSE:PERF) is one of the 7 most popular AI penny stocks under $5 to avoid. On June 11, Perfect revealed a 'groundbreaking' partnership with Nvidia (NASDAQ:NVDA) to enhance its suite of next-generation beauty and fashion technology solutions. Specifically, Perfect will integrate Nvidia's AI and accelerate computing platforms into its products. According to Perfect, this integration will help to deliver hyper-personalized experiences with unparalleled realism, accuracy, and speed in the beauty and fashion industries. A fashion model in a stunning and stylish outfit leveraging augmented reality beauty and fashion tech. Perfect's AI Skincare solution uses deep-learning AI models trained on over 70,000 medical-grade images to detect up to 15 skin conditions in real time. It is optimized with NVIDIA TensorRT for lightning-fast runtime performance. On the other hand, YouCam Online Editor offers Generative AI features, including AI Hairstyle Generation and AI Video Face Swap. This, too, leverages NVIDIA TensorRT, which optimizes generative diffusion models for real-time creation of personalized hairstyles, face swaps, and clothing try-ons. Thus, integrating Nvidia's technology into the solutions addresses several critical challenges. The main ones are achieving true-to-life color representation and adapting to diverse skin tones and types. Perfect Corp. (NYSE:PERF) is an AI and augmented reality software company headquartered in New Taipei City, Taiwan. The firm creates digital solutions for the beauty, fashion, and skincare industries. Its key products include the YouCam app suite and the WANNA virtual try-on platform. While we acknowledge the potential of PERF as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs China Stocks: 10 Stocks to Buy and 10 Undervalued Blue Chip Stocks Analysts Recommend for Smart Investing. Disclosure: None. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
BTIG Lifts Super Group (SGHC) PT to $11, Reiterates Buy Rating
Super Group Limited (NYSE:SGHC) is one of the best mid cap growth stocks to invest in now. Earlier on June 11, BTIG analyst Clark Lampen increased the price target for Super Group to $11 from $9, while reiterating a Buy rating on the shares. This adjustment reflects BTIG's updated financial model, which incorporates Super Group's recent change in presentation currency and a more favorable outlook for its Sportsbook operations in FY2025 and FY2026. In Q1 2025, Super Group's total revenue reached an all-time high of $517 million, which marked a 25% increase year-over-year. Revenue excluding the US market was $502 million, which was up 24% year-over-year. The company's unique monthly active customers averaged 5.4 million for the quarter, which was a 14% increase from 4.7 million in Q1 2024. A reputable investor betting on a sports event, confidently placing a wager online. Specifically, sports betting grew 7% while casino operations saw a 23% increase. Geographically, Africa's revenue grew by 54% due to strong performance in South Africa, Ghana, Malawi, and the successful launch in Botswana. European revenue increased by 53%, with the UK market showing particularly strong growth of 87% due to the performance of Jackpot City and Betway. Canada's revenue also grew by 13%. However, the APEC region experienced a 13% decline due to currency weakness and the closure of non-performing markets. Super Group Limited (NYSE:SGHC) operates as an online sports betting and gaming operator. While we acknowledge the potential of SGHC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
